Renee N Donahue

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 32

Top Topics

Small Cell Lung Cancer

Circulating Tumor

Metastatic Colorectal Cancer

Top Venues

Nature communications

Journal for immunotherapy of cancer

Journal of experimental & clinical cancer research : CR

Clinical and translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. Journal for immunotherapy of cancer 12 (3) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Yo-Ting Tsai, Jeffrey Schlom, Renee N Donahue
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. Journal for immunotherapy of cancer 12 (3) (2024)
Stephanie C Pitts, Jeffrey Schlom, Renee N Donahue
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Jeffrey Schlom, Renee N Donahue, Claudia Palena, Sofia R Gameiro, James W Hodge, Duane H Hamilton, James L Gulley
Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines. Journal for immunotherapy of cancer 12 (7) (2024)
Yo-Ting Tsai, Jeffrey Schlom, Renee N Donahue
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Stephanie C Pitts, Jeffrey Schlom, Renee N Donahue
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. Journal for immunotherapy of cancer 12 (3) (2024)
Meghali Goswami, Nicole J Toney, Stephanie C Pitts, Carolina Celades, Jeffrey Schlom, Renee N Donahue
Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours. Clinical and translational medicine 14 (8) (2024)
Yo-Ting Tsai, Jeffrey Schlom, Renee N Donahue
Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Meghali Goswami, Nicole J Toney, Stephanie C Pitts, Carolina Celades, Jeffrey Schlom, Renee N Donahue
Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours. Clinical and translational medicine 14 (8) (2024)
Manjari Kundu, Yoshimi Endo Greer, Alexei Lobanov, Lisa A Ridnour, Renee N Donahue, Yeap Ng, Shashi Ratnayake, Donna Voeller, Sarah Weltz, Qingrong Chen, Stephen J Lockett, Maggie Cam, Daoud Meerzaman, David A Wink, Roberto Weigert, Stanley Lipkowitz
TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers. bioRxiv : the preprint server for biology (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. Journal for immunotherapy of cancer 12 (3) (2024)
Stephanie C Pitts, Jeffrey Schlom, Renee N Donahue
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies. Journal of experimental & clinical cancer research : CR 43 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Filipa C Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Ilana Schlam, Hongkun Wang, Nicole J Toney, Caroline Jochems, Jeffrey Schlom, Jay Zeck, Christopher M Gallagher, Rita Nanda, Deena Graham, Erica M Stringer-Reasor, Neelima Denduluri, Julie M Collins, Ami Chitalia, Shruti Tiwari, Raquel A Nunes, Rebecca Kaltman, Katia Khoury, Margaret Gatti-Mays, Paolo Tarantino, Sara M Tolaney, Sandra M Swain, Paula Pohlmann, Heather A Parsons, Claudine Isaacs
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nature communications 15 (1) (2024)
Meghali Goswami, Nicole J Toney, Stephanie C Pitts, Carolina Celades, Jeffrey Schlom, Renee N Donahue
Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours. Clinical and translational medicine 14 (8) (2024)
Julius Strauss, Jean-Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K Pachynski, Theodore S Gourdin, Michele Maio, Luc Dirix, Jeffrey Schlom, Renee N Donahue, Yo-Ting Tsai, XiaoZhe Wang, Yulia Vugmeyster, Frank Beier, Joerg Seebeck, Andreas Schroeder, Sarah Chennoufi, James L Gulley
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. Journal for immunotherapy of cancer 11 (5) (2023)
Nicole J Toney, Jeffrey Schlom, Renee N Donahue
Phosphoflow cytometry to assess cytokine signaling pathways in peripheral immune cells: potential for inferring immune cell function and treatment response in patients with solid tumors. Journal of experimental & clinical cancer research : CR 42 (1) (2023)
Jonathan Hsu, Renee N Donahue, Madan Katragadda, Jessica Lowry, Wei Huang, Karunya Srinivasan, Gurkan Guntas, Jian Tang, Roya Servattalab, Jacques Moisan, Yo-Ting Tsai, Allart Stoop, Sangeetha Palakurthi, Raj Chopra, Ke Liu, E John Wherry, Zhen Su, James L Gulley, Andrew Bayliffe, Jeffrey Schlom
A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity. Science translational medicine 15 (724) (2023)
Yo-Ting Tsai, Julius Strauss, Nicole J Toney, Caroline Jochems, David J Venzon, James L Gulley, Jeffrey Schlom, Renee N Donahue
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. Journal for immunotherapy of cancer 10 (4) (2022)